|
 The European Commission has approved the lung cancer drug as an
add-on treatment for adults diagnosed early enough for the tumour to
be surgically removed, and who have a mutation of the EGFR gene, the
British drugmaker said.
The approval was based on positive results from a late-stage trial
called ADAURA, which showed Tagrisso cut the risk of the tumour
growing back in patients or death by 80%.
The drug is now approved to treat early-stage lung cancer in more
than 50 countries, including, most recently, in the United States
and China.
[to top of second column] |
 Tagrisso brought in sales of
$1.15 billion in the first quarter, the company
said in April.
The EGFR mutation is found in about a quarter of
global lung cancer cases, and the older
generation of EGFR inhibitors include Roche's
Tarceva and AstraZeneca's Iressa.
(Reporting by Vishwadha Chander in Bengaluru;
Editing by Devika Syamnath
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
